Select therapeutic use:
Indications for TRULICITY:
Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
Limitations Of use:
Not recommended as first-line treatment for patients inadequately controlled on diet and exercise. Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes or diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients with pre-existing severe GI disease.
Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; may increase to max 1.5mg once weekly if inadequate response. Renal impairment: caution with initiating or escalating doses.
<18yrs: not recommended.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors.
Risk of thyroid C-cell tumors; inform patients of risk and symptoms. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis; consider other antidiabetic therapies. Discontinue if hypersensitivity reactions occur; treat promptly and monitor until resolve. History of angioedema or anaphylaxis. Monitor renal function in renally-impaired patients reporting severe GI reactions. Hepatic impairment. Pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Increased risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing their doses. May affect absorption of other oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia; acute pancreatitis.
Single-dose pen—4; Single-dose prefilled syringe—4